Torres-Cornejo, A.BenMarzouk-Hidalgo, O. J.Viciana, P.Sanchez, B.Lopez-Ruz, M. A.Lopez-Cortes, L. F.Gutierrez-Valencia, A.2023-02-122023-02-122016-01-011198-743Xhttp://hdl.handle.net/10668/18746Cross-sectional study comparing seminal human immunodeficiency virus type 1 (HIV-1) shedding in patients receiving boosted protease inhibitor monotherapy (mtPI/rtv) (n = 66) versus triple therapy (TT) (n = 61). Seminal HIV-1 shedding rates in patients with undetectable plasma HIV-RNA were 16.0% on mtPI/rtv compared with 28.6% on TT (p 0.173). Aviraemic status and time on viral suppression were independently associated with lack of seminal HIV-1 shedding. During TT, non PI/rtv-based regimens were associated with a better control of HIV infection in semen despite similar time on viral suppression. The use of mtPI/rtv in well-controlled patients is not associated with increased seminal HIV excretion compared with TT. (C)2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.enHuman immunodeficiency virus 1 infectionhuman immunodeficiency virus 1 treatmentmale genital tractprotease inhibitor monotherapytriple therapyViral loadBlood-plasmaHiv-1 rnaSemenLopinavir/ritonavirMenRitonavirresearch articleopen access10.1016/j.cmi.2015.09.0281469-0691http://www.clinicalmicrobiologyandinfection.com/article/S1198743X15008988/pdf368024800032